David A. Siegel Viracta Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.89 - $2.13 $2,670 - $6,390	-3,000 Reduced 19.09%	12,719 $17,000
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $34,914 - $57,937	-25,300 Reduced 61.68%	15,719 $24,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $37,697 - $131,045	29,919 Added 269.54%	41,019 $59,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $6,308 - $10,811	-1,900 Reduced 14.62%	11,100 $47,000
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $8,261 - $22,090	-4,418 Reduced 25.36%	13,000 $50,000
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $68,518 - $146,255	-30,726 Reduced 63.82%	17,418 $83,000
Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $162,245 - $380,819	48,144 New	48,144 $176,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.